Medtronic PLC $MDT Shares Sold by Parthenon LLC

Parthenon LLC trimmed its position in Medtronic PLC (NYSE:MDT) by 17.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 71,969 shares of the medical technology company’s stock after selling 15,268 shares during the period. Parthenon LLC’s holdings in Medtronic were worth $6,854,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Delos Wealth Advisors LLC purchased a new stake in shares of Medtronic during the second quarter worth approximately $27,000. Corundum Trust Company INC purchased a new stake in shares of Medtronic during the third quarter worth $27,000. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medtronic during the third quarter worth $33,000. Tripletail Wealth Management LLC acquired a new stake in shares of Medtronic in the third quarter valued at about $34,000. Finally, GFG Capital LLC purchased a new position in shares of Medtronic in the second quarter worth about $36,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Price Performance

Shares of MDT opened at $100.98 on Monday. The firm has a 50-day simple moving average of $99.44 and a two-hundred day simple moving average of $95.32. The stock has a market cap of $129.45 billion, a PE ratio of 27.22, a P/E/G ratio of 2.66 and a beta of 0.71. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter last year, the company posted $1.26 EPS. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. Medtronic’s payout ratio is presently 76.55%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MDT. Wall Street Zen raised shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Friday. Wells Fargo & Company upped their price target on Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Jefferies Financial Group reiterated a “hold” rating and set a $110.00 price objective on shares of Medtronic in a research report on Wednesday, November 19th. Royal Bank Of Canada upped their target price on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. Finally, Sanford C. Bernstein raised their target price on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Fourteen equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $110.28.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).